Sexually Transmitted Disease Surveillance 2011 Division of STD Prevention

Gonorrhea—Rates, United States, 1941– Fig 16. SR

Gonorrhea—Rates by Sex, United States, 1991– Fig 17. SR

Gonorrhea—Rates by Region, United States, 2002– Fig 18. SR

Gonorrhea—Rates by State, United States and Outlying areas, 2011 NOTE: The total rate of gonorrhea for the United States and outlying area (Guam, Puerto Rico, and Virgin Islands) was per 100,000 population Fig 19. SR

Gonorrhea—Rates by County, United States, Fig 20. SR

Gonorrhea—Rates by Age and Sex, United States, Fig 21. SR

Gonorrhea—Rates by Age Among Women Aged 15–44 Years, United States, 2002– Fig 22. SR

Gonorrhea—Rates by Age Among Men Aged 15–44 Years, United States, 2002– Fig 23. SR

Gonorrhea—Rates by Race/Ethnicity, United States, 2002– Fig 24. SR

Gonorrhea—Cases by Reporting Source and Sex, United States, 2002– Fig 25. SR

Gonorrhea—Percentage of Reported Cases by Sex and Selected Reporting Sources, United States, 2011 *HMO=health maintenance organization; HD=health department NOTE: These categories represent 66.5% of cases with a known reporting source. Of all cases, 11.7% has a missing or unknown reporting source Fig 26. SR

Proportion MSM*, MSW*, and Women Among Interviewed † Gonorrhea Cases by Site, STD Surveillance Network (SSuN), 2011 *MSM=men who have sex with men; MSW=men who have sex with women only. †SSuN interviews conducted in a randomly selected sample of the patient population with gonorrhea (n=4,540). ‡California data excludes San Francisco. NOTE: See Appendix for included jurisdictions within each state Fig 27. SR

Gonorrhea—Positivity Among Women Aged 15–24 Years Tested in Family Planning Clinics, by State, Infertility Prevention Project, United States and Outlying Areas, 2011 *States/areas had incomplete data or reported gonorrhea positivity data on fewer than 500 women aged years in Fig 28. SR

Location of Participating Sentinel Sites and Regional Laboratories, Gonococcal Isolate Surveillance Project (GISP), United States, 2011 *NOTE: The Austin site is a regional laboratory only Fig 29. SR

Distribution of Minimum Inhibitory Concentrations (MICs) of Ceftriaxone Among Neisseria gonorrhoeae Isolates, Gonococcal Isolate Surveillance Project (GISP), 2007– Fig 30. SR

Distribution of Minimum Inhibitory Concentrations (MICs) of Cefixime Among Neisseria gonorrhoeae Isolates, Gonococcal Isolate Surveillance Project (GISP), 2009–2011 NOTE: Isolates were not tested for cefixime susceptibility in 2007 and Fig 31. SR

Distribution of Minimum Inhibitory Concentrations (MICs) of Azithromycin Among Neisseria gonorrhoeae Isolates, Gonococcal Isolate Surveillance Project (GISP), 2007– Fig 32. SR

Percentage of Neisseria gonorrhoeae Isolates that are Ciprofloxacin-Resistant by Sex of Sex Partner, Gonococcal Isolate Surveillance Project (GISP), 1995–2011 *MSM=men who have sex with men; MSW=men who have sex with women only Fig 33. SR

Penicillin, Tetracycline, and Ciprofloxacin Resistance Among Neisseria gonorrhoeae Isolates, Gonococcal Isolate Surveillance Project (GISP), 2011 NOTE: PenR = penicillinase producing Neisseria gonorrhoeae and chromosomally mediated penicillin-resistant N. gonorrhoeae; TetR = chromosomally and plasmid mediated tetracycline-resistant N. gonorrhoeae; and QRNG = quinolone-resistant N. gonorrhoeae Fig 34. SR

Antimicrobial Drugs Used to Treat Gonorrhea Among Participants, Gonococcal Isolate Surveillance Project (GISP), 1988–2011 NOTE: For 2011, “Other” includes no therapy (1.2%), azithromycin 2g (2.3%), and other less frequently used drugs Fig 35. SR